FDA Panel Not Persuaded By Effectiveness Of BioMarin Duchenne Muscular Dystrophy Drug U.S. Food and Drug Administration advisers were not convinced of BioMarin Muscular Dystrophy drug's efficacy based on clinical trials. Drisapersen, fell short in proving its effectiveness in patients suffering from Duchenne muscular dystrophy. by Angela Laguipo
'Spray and Pray' iMessage Scam Haunts iPhone Owners: How to Avoid Losing Your Hard-Earned Money From it